'Tecos hospitalization' presentation slideshows

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus. DPP-4 Inhibitor CV Outcomes Trials in T2DM. T2DM CV Outcomes Trials From the DPP-4 Inhibitor Class. SAVOR-TIMI 53: Primary Endpoint. SAVOR-TIMI 53: Hospitalization for HF. EXAMINE: Primary Endpoint. EXAMINE: Hospitalization for HF.

673 views • 46 slides